Key facts
- Levi & Korsinsky is investigating Oculis Holding AG officers and directors.
- Oculis Holding AG's OCS-01 DME program's Phase 3 DIAMOND trials failed.
- Oculis Holding AG shares fell over 23% following the trial failure announcement.
- Allegations suggest SEC filings described the program as on track for FDA submission despite trial failure.
Securities fraud investigations are often initiated when a company's public statements are alleged to be misleading, particularly concerning clinical trial outcomes or regulatory submissions. Such investigations can lead to legal action on behalf of affected investors, especially when stock prices react sharply to new information that contradicts previous company disclosures.